Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON: Iberdomide + low-dose cyclophosphamide + dexamethasone in relapsed/refractory multiple myeloma
2019-004604-35Phase 2Active
- Sponsor
- VU University Medical Center
- Start
- Jun 2020
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iberdomide in multiple myeloma (MM), sponsored by VU University Medical Center. Primary endpoint: Progression-free survival. Started Jun 2020; status: active.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2019-004604-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004604-35.